LLYVA Q4 2025 Earnings EPS Slightly Misses Estimates Amid Resilient Live Entertainment Demand SENEB Q1 2026 Earnings Reported EPS of 619 No Street Estimate Available SVRA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues Pipeline Progress ASND Q1 2026 Earnings EPS Misses Estimates as Ascendis Pharma Navigates Cost Pressures NTLA Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Stage Company Focuses on Pipeline Execution WRB Q1 2026 Earnings Strong Underwriting and Investment Performance Drive 124 EPS Beat